Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Mar 6, 2019 (8 years ago)

Losartan Potassium Tablets

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

CGMP Deviations: presence of an impurity, N-Methylnitrosobutyric acid (NMBA) was identified.

Cause type: Nitrosamine impurity

Trace nitrosamine impurities such as NDMA, NDEA or NMBA found above the acceptable daily limit. Nitrosamines are probable human carcinogens that can form during manufacturing or storage. This is the cause behind the large valsartan, losartan and ranitidine (Zantac) recalls. All nitrosamine impurity recalls.

What was recalled

Losartan Potassium Tablets, USP, 50 mg, a) 30-count bottle (NDC: 68788-0048-03), b) 90-count bottle (NDC: 68788-0048-09), Rx Only, Mfg: Torrent Pharma Inc. Basking Ridge, NJ. Relabeled by: Preferred Pharmaceuticals, Inc. 1250 N. Lakeview Ave., Suite O, Anaheim, CA 92807.

Affected NDCs 68788-0048-03 68788-0048-09

Compare with the code on your package — it is the most precise check available.

Drug: Losartan Category: Blood Pressure Medication

Recalling firm
Preferred Pharmaceuticals, Inc
Origin
CA, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1051-2019 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Losartan recalls

See all

Other recalls by Preferred Pharmaceuticals, Inc

All 2019 recalls
Class II · Moderate risk

Ondansetron ODT Tablets

Defective container: Preferred Pharmaceuticals received a letter from the manufacturer Glenmark, that the blister packs are not fully sealed and tablets falling out. Preferred Pharmaceuticals purchased the finished product and repackaged the product for sale.

Ongoing Packaging defect Preferred Pharmaceuticals, Inc. NDC 68788-8666-01 D-0239-2026
Class II · Moderate risk

Ibuprofen Tablets

Failed Impurities/Degradation Specifications - at 18-month Stability testing

Ongoing Impurity / degradation Preferred Pharmaceuticals, Inc. NDC 68788-9110-03 D-0647-2024